Oral Fludarabine | springermedicine.com

Springer Medicine

Top

Drugs

Published in:

01-11-2003 | Adis Drug Profile

Oral Fludarabine

A Viewpoint by Bruce D. Cheson

Author: Bruce D. Cheson

Published in: Drugs | Issue 21/2003

Excerpt

A bit more than a decade ago, the treatment of indolent lymphoid malignancies, particularly chronic lymphocytic leukemia (CLL), underwent the first of two major revolutions. Alkylating agents, such as chlorambucil, had been the standard of care, but were quite unsatisfactory. Over the ensuing years, randomised clinical trials demonstrated the superiority of the purine analogue fludarabine with respect to overall and complete response rates, duration of response and time to progression. Unfortunately, prolongation of survival has been elusive. …

Title: Oral Fludarabine
A Viewpoint by Bruce D. Cheson
Author: Bruce D. Cheson
Publication date: 01-11-2003
Publisher: Springer International Publishing
Published in: Drugs / Issue 21/2003
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200363210-00007

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 21/2003

Improving Health-Related Quality of Life in Gastro-Oesophageal Reflux Disease